Jim Cramer's 'Mad Money' Recap: Got Growth?

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK ( TheStreet) -- Where can investors find the best growth stocks? All over place, if you know where to look, Jim Cramer said on "Mad Money" Tuesday.

In the biotech space, Cramer called out Regeneron ( REGN) as one such stock -- it has growth today and, thanks to a robust pipeline of new drugs, for many years to come. The oil patch is littered with high-growth stocks, including EOG Resources ( EOG), Cramer continued.

Restaurants Red Robin Gourmet Burgers ( RRGB) and Starbucks ( SBUX) both have growth, as do retailers Michael Kors ( KORS), which delivered a 49% increase in profits and a 23% increase in sales this quarter.

Cramer said just about any stock that deals with mobile, social media or the cloud is growing like gangbusters -- which leads right to this week's Twitter IPO. Just a few weeks ago, Cramer noted, he was at the high end of the range, saying Twitter could be worth up to $20 billion. But today, despite nothing factually changing, $20 billion seems at the low end of the range, with some calling for valuations as high as $50 billion for Twitter.

Cramer said that's a recipe for investors to get hurt, a la the Facebook ( FB) IPO last year. He cautioned that the big boys are betting big that uninformed investors will be willing to pay anything for shares of Twitter -- which is why he's once again reminding everyone there are prices at which every stock just becomes uninvestable.

Cramer said he's willing to pay up to $28 a share for Twitter and not a penny more.

Executive Decision:

In the "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics ( ACOR), a stock that's up 31% so far in 2013 and just delivered a 16-cents-a-share earnings beat.

Cohen said sales of Acorda's multiple sclerosis drug, Ampyra, is the engine that's helping to drive the company forward and Acorda is very fortunate to have such a successful product. Acorda is not a one-hit wonder, however, as the company now has six drugs in clinical studies, including new formulations of ingredients of Amypra that may treat strokes and other conditions.

Acorda is also working towards better treatments for the 2.3 million people that suffer from epilepsy. Cohen said current drugs that come in suppository form have not been well received, but Acorda's new nasal formulation holds a lot of promise for this very important market.

Cohen also commented on Acorda's efforts to combat spinal cord injuries. He said Acorda was founded to help in this area. While results are still several years away, the current clinical trials also hold a lot of promise.

Cramer said Acorda remains one of his favorites in the biotech group.

Executive Decision: Leonard Schleifer

In his second "Executive Decision" segment, Cramer sat down with Dr. Leonard Schleifer, president and CEO of Regeneron, which just posted the biggest earnings beat of the year, a full 52 cents a share ahead of analyst expectations. Shares of Regeneron are up 65% since Cramer last checked in with Schleifer back in January.

Schleifer said there's a lot going on at Regeneron and he's very blessed to be at a company where every aspect of its business is working and working well. He noted the company's macular degeneration drug, Eylea, continues to grow, even with threats of increased competition. Also, his company has promising drugs in the pipeline to treat high cholesterol and asthma, among other conditions. As Schleifer put it, there are a lot of great things to spend money on at Regeneron.

When asked about the impact of new regulations from the Food and Drug Administration, Schleifer said the FDA's efforts to set broader quality standards will be a good thing for all those involved in making and selling drugs.

Looking at Regeneron's pipeline, Schleifer said there are 13 new products currently in clinical trials and a bunch more the company is not even talking about yet.

Cramer told viewers to listen to Regeneron's conference call to hear firsthand why he's so excited about this company, even at $300 a share.

Lightning Round

In the Lightning Round, Cramer was bullish on US Airways Group ( LCC), Carrizo Oil & Gas ( CRZO), Petrobras ( PBR), Alcoa ( AA), ConocoPhillips ( COP) and United Rentals ( URI).

Cramer was bearish on Rambus ( RMBS), Matador Resources ( MTDR) and Merck ( MRK).

Executive Decision: Jeffrey Stoops

In a third "Executive Decision" segment, Cramer spoke with Jeffrey Stoops, president and CEO of SBA Communications ( SBAC), the cell-tower operator whose shares are up 250% since Cramer first called the bull market in cell towers in October 2009.

Stoops said SBA's growth is being driven by consumer demand for more and better wireless services. That's why all of the major carriers are investing heavily in their infrastructure to provide their customers a better experience. Stoops said the race to build the best 4G and LTE networks is heating up, with Sprint ( S) and T-Mobile ( TMUS) working aggressively to close the gap with AT&T ( T) and Verizon ( VZ).

Stoops also noted that SBA continues to be entrepreneurial in nature, building a strong portfolio of high-quality assets with strong organic growth.

When asked about the possibility of converting into a real estate investment trust and sending more of the company's profits to shareholders, Stoops said eventually SBA will make that transition, but now is not the time because there's still a lot of growth to be had and investors are benefiting from SBA's dividend payout.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer reminded investors they can profit from secondary offerings of stock as well as initial offerings.

That was certainly the case with Yelp ( YELP) and Western Digital ( WDC), said Cramer. Both of these recent secondary offerings afforded investors great opportunities to pick up a few dollars a share in the blink of an eye.

That's why Cramer is also excited about an upcoming secondary for Carrizo Oil & Gas, which is looking to raise capital to finance its acquisitions. Cramer said with Carrizo already posting record earnings and profits, it's hard to see how investors wouldn't profit from this deal as well.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had a position in FB.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for TheStreet.com, Inc., and CNBC, and a director and co-founder of TheStreet.com. All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of TheStreet.com or its affiliates, or CNBC, NBC Universal or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither TheStreet.com, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or TheStreet.com is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, TheStreet.com or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor TheStreet.com, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on TheStreet.com. The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in TheStreet.com, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.

More from Jim Cramer

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer on Foot Locker's Earnings: Nike Is a Buy

Jim Cramer on Foot Locker's Earnings: Nike Is a Buy